Sanofi

The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.

Berg will use its Interrogative Biology platform in order to assess potential biomarkers of seasonal influenza vaccination outcomes.

To Interfere

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.

Sanofi recruits one of AstraZeneca's top scientists to bolster its biotech presence, Reuters reports.

The collaboration will focus on identifying new signaling pathways and targets involved in coronary artery disease.

The study used a modified version of Myriad RBM's DiscoveryMAP immunoassay panel to measure levels of 237 proteins in blood samples from 8,401 patients.

The pharma firm joins Pfizer Canada and AstraZeneca in the National Access Project, which tests tumors for mutations to match patients with potential therapies.

The two methods could shorten the detection time by eliminating the need to amplify the virus with in vitro cell culture.

The data show that RG-012 can enhance the effect of Sanofi's kidney protectant ramipril and suggest the microRNA drug might have use in other chronic kidney diseases.

Pages

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.